Financial Performance - Revenue for Q2 2025 was $1,863,654, a 1% increase from $1,836,597 in Q2 2024, marking a new quarterly record for the Company[5] - Consolidated clinic revenue increased by 1% to $1,832,094 compared to $1,807,921 in the previous year[5] - Net loss from continuing operations was $(3.2) million, compared to $(2.2) million in Q2 2024[5] - Adjusted EBITDA for Q2 2025 was $(587,230), compared to $(509,623) in Q2 2024[5] - Total revenue from all clinics, including consolidated and equity method clinics, was $2,188,893, a 2% increase from $2,141,229[5] Operational Developments - The Company launched telehealth capabilities at its Wisconsin clinic to enhance patient access to fertility care[5] - A new patent for a modified version of the INVOcell device was allowed, extending intellectual property protection through 2040[5] - The Wisconsin Fertility Institute was recognized on Newsweek's List of America's Best Fertility Clinics for 2025[5] - The Company completed the divestiture of NAYA Therapeutics, allowing a focus on fertility operations[6] - Management emphasized a commitment to maintaining an efficient operating structure while pursuing complementary revenue-generating opportunities[7]
NAYA Biosciences, Inc.(NAYA) - 2025 Q2 - Quarterly Results